BreakBio, the Third Player in Personalized Drugs, Enters the Clinic
BreakBio, the Third Player in Personalized Drugs, Enters the Clinic
PR Newswire
MIAMI, Aug. 24, 2026
MIAMI, Aug. 24, 2026 /PRNewswire/ -- BreakBio, the third player in personalized drugs after Moderna and BioNTech and the top private company in the personalized drugs space with advanced cutting-edge technology, is entering the clinic next quarter. BreakBio aims to be not first-in-class but best-in-class. It is designed for both higher efficacy than Moderna or BioNTech and it is also designed to treat more cancer indications than Moderna or BioNTech.
- BreakBio is designed for higher efficacy than Moderna's individualized neoantigen therapy (INT). Higher efficacy because BreakBio is designed to find better targets per patient. It is an AI first biotech company. For every patient, its platform integrates highest quality tumor DNA sequencing, RNA sequencing, mass-spectrometry-based immunopeptidomics (of that patient) with proprietary deep AI analysis to find better targets on that patient's cancer cells. Better targets means killing more (or all) of the cancer cells.
- BreakBio is designed to extend personalized drugs to more cancer indications than Moderna. BreakBio achieves this by targeting not just neoantigens (associated with mutations as Moderna and BioNTech do) but it also searches for and finds, in each patient, some of the hundreds of cancer-associated non-mutated proteins such as cancer testis antigens, embryonic antigens, etc. - so BreakBio is designed to also work for low mutational cancers, which means it is designed to work for all solid cancers both high mutational cancers like melanoma and low mutational cancers like colorectal.
About BreakBio:
BreakBio is a new generation of personalized cancer drugs designed to deliver both greater efficacy per patient and treat a broader range of cancers than today's individualized neoantigen therapy competitor. The company combines mass spectrometry, machine learning, and its proprietary AI platform to design and manufacture individualized peptide-based medicines tailored to each patient's cancer and combines them with approved cancer therapies to drive deeper and more durable anti-tumor responses.
Unlike approaches focused only on mutation-related neoantigen targets found in high-mutational cancers like melanoma, BreakBio targets neoantigens, but also targets non-mutated antigens (found by its AI platform per patient) in order to broaden the treatment to all solid tumors.
Media Contact:
Kim Nancarrow
COO/CFO
BreakBio Corp.
info@breakbio.com
SOURCE BreakBio Corp.
The articles, information, and content displayed on this webpage may include materials prepared and provided by third parties. Such third-party content is offered for informational purposes only and is not endorsed, reviewed, or verified by Morningstar.
Morningstar makes no representations or warranties regarding the accuracy, completeness, timeliness, or reliability of any third-party content displayed on this site. The views and opinions expressed in third-party content are those of the respective authors and do not necessarily reflect the views of Morningstar, its affiliates, or employees.
Morningstar is not responsible for any errors, omissions, or delays in this content, nor for any actions taken in reliance thereon. Users are advised to exercise their own judgment and seek independent financial advice before making any decisions based on such content. The third-party providers of this content are not affiliated with Morningstar, and their inclusion on this site does not imply any form of partnership, agency, or endorsement.
Popular
2 Undervalued Stocks to Buy With Long-Term Growth Ahead
4 Stocks to Buy for the Long-Term While They’re Still Undervalued
Why This Vanguard ETF Is One of the Best
The Market May Be Too Pessimistic About This 4-Star Dividend Stock
United States